Y
Yuji Mishina
Researcher at Novartis
Publications - 13
Citations - 2719
Yuji Mishina is an academic researcher from Novartis. The author has contributed to research in topics: Fusion gene & Cancer. The author has an hindex of 11, co-authored 13 publications receiving 2445 citations. Previous affiliations of Yuji Mishina include Harvard University.
Papers
More filters
Journal ArticleDOI
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
Shih Min A Huang,Yuji Mishina,Shanming Liu,Atwood K. Cheung,Frank Stegmeier,Gregory A. Michaud,Olga Charlat,Elizabeth Wiellette,Yue Zhang,Stephanie Wiessner,Marc Hild,Xiaoying Shi,Christine D. Wilson,Craig Mickanin,Vic E. Myer,Aleem Fazal,Ronald Tomlinson,Fabrizio C. Serluca,Wenlin Shao,Hong Cheng,Michael Shultz,Christina Rau,Markus Schirle,Judith Schlegl,Sonja Ghidelli,Stephen Fawell,Chris Lu,Daniel Curtis,Marc W. Kirschner,Christoph Lengauer,Peter Finan,John A. Tallarico,Tewis Bouwmeester,Jeffery A. Porter,Andreas Bauer,Feng Cong +35 more
TL;DR: This study uses a chemical genetic screen to identify a small molecule, XAV939, which selectively inhibits β-catenin-mediated transcription and reveals new mechanistic insights into the regulation of axin protein homeostasis, which presents new avenues for targeted Wnt pathway therapies.
Journal ArticleDOI
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A - TCF7L2 fusion
Adam J. Bass,Adam J. Bass,Michael S. Lawrence,Lear E. Brace,Alex H. Ramos,Alex H. Ramos,Yotam Drier,Kristian Cibulskis,Carrie Sougnez,Douglas Voet,Gordon Saksena,Andrey Sivachenko,Rui Jing,Melissa Parkin,Trevor J. Pugh,Trevor J. Pugh,Roel G.W. Verhaak,Nicolas Stransky,Adam T. Boutin,Jordi Barretina,David B. Solit,Evi Vakiani,Wenlin Shao,Yuji Mishina,Markus Warmuth,Jose Jimenez,Derek Y. Chiang,Sabina Signoretti,William G. Kaelin,Nicole Spardy,William C. Hahn,William C. Hahn,Yujin Hoshida,Shuji Ogino,Ronald A. DePinho,Lynda Chin,Levi A. Garraway,Levi A. Garraway,Charles S. Fuchs,Jose Baselga,Jose Baselga,Josep Tabernero,Stacey Gabriel,Eric S. Lander,Eric S. Lander,Gad Getz,Matthew Meyerson,Matthew Meyerson +47 more
TL;DR: Previously unidentified levels of genomic rearrangements in colorectal carcinoma that can lead to essential gene fusions and other oncogenic events are shown.
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion
Adam J. Bass,Adam J. Bass,Michael S. Lawrence,Lear E. Brace,Alex H. Ramos,Alex H. Ramos,Yotam Drier,Kristian Cibulskis,Carrie Sougnez,Douglas Voet,Gordon Saksena,Andrey Sivachenko,Rui Jing,Melissa Parkin,Trevor J. Pugh,Trevor J. Pugh,Roel G.W. Verhaak,Nicolas Stransky,Adam T. Boutin,Jordi Barretina,David B. Solit,Evi Vakiani,Wenlin Shao,Yuji Mishina,Markus Warmuth,Jose Jimenez,Derek Y. Chiang,Sabina Signoretti,William G. Kaelin,Nicole Spardy,William C. Hahn,William C. Hahn,Yujin Hoshida,Shuji Ogino,Ronald A. DePinho,Lynda Chin,Levi A. Garraway,Levi A. Garraway,Charles S. Fuchs,Jose Baselga,Jose Baselga,Josep Tabernero,Stacey Gabriel,Eric S. Lander,Eric S. Lander,Gad Getz,Matthew Meyerson,Matthew Meyerson +47 more
TL;DR: In this paper, the authors identify an average of 75 somatic rearrangements per tumor, including complex networks of translocations between pairs of chromosomes, which can lead to essential gene fusions and other oncogenic events.
Journal ArticleDOI
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
George Scott Tria,Tinya Abrams,Jason Baird,Burks Heather Elizabeth,Brant Firestone,L. Alex Gaither,Lawrence G. Hamann,He Guo,Christina A. Kirby,Sunkyu Kim,Franco Lombardo,Kaitlin J. Macchi,Donald P. McDonnell,Yuji Mishina,John D. Norris,Jill Nunez,Clayton Springer,Yingchuan Sun,Noel Marie-France Thomsen,Chunrong Wang,Jianling Wang,Bing Yu,Choi-Lai Tiong-Yip,Stefan Peukert +23 more
TL;DR: The design and synthesis of a series of potent benzothiophene-containing compounds that exhibit oral bioavailability and preclinical activity as SERDs are described, culminating in the identification of LSZ102, a compound in clinical development for the treatment of ERα positive breast cancer.
Journal ArticleDOI
Multiplex GPCR Assay in Reverse Transfection Cell Microarrays
Yuji Mishina,Chris Wilson,Linda Bruett,Jesse J. Smith,Chatanika Stoop-Myer,Sena Jong,Lizabeth P. Amaral,Robin Pedersen,Susan K. Lyman,Vic E. Myer,Brent L. Kreider,Craig M. Thompson +11 more
TL;DR: The authors demonstrate the utility of reverse transfection cell microarrays to GPCR-targeted drug discovery with examples of ligand selectivity screening against a panel of GPCRs as well as dose-dependent titrations of selected agonists and antagonists.